Literature DB >> 21295156

Is the tissue persistence of O(6)-methyl-2'-deoxyguanosine an indicator of tumour formation in the gastrointestinal tract?

Shir Ley Tan1, Jacobus P Gerber, Leah J Cosgrove, Trevor J Lockett, Julie M Clarke, Desmond B Williams, Richard J Head.   

Abstract

Azoxymethane (AOM) is a methylating agent capable of inducing mutations in DNA by forming adducts with DNA bases. It has been used to understand the mechanisms involved in colon carcinogenesis. Of the adducts formed in response to AOM, O(6)-methyl-2'-deoxy-guanosine (O(6)-mdGua) is the most mutagenic. Based on studies in rodents of the abundance and persistence of DNA adducts in various tissues after treatment with alkylating agents, previous results suggest, as a generalization, that the longer O(6)-mdGua adducts remain unrepaired in the cells of a tissue, the greater the risk for tumorigenesis. To test this hypothesis, we have built on these studies, expanding the number of tissues in which O(6)-mdGua abundance and persistence were examined and correlating these data with tumour distribution and abundance in rats maintained for 26 weeks after the treatment with AOM. Our study revealed firstly the existence of groups of tissues that developed relatively large amounts (proximal and distal colon, proximal small intestine (SI), liver and kidney) and relatively low levels (stomach, distal SI, bladder, spleen, blood and lung) of O(6)-mdGua after AOM exposure. Secondly, while all tissues showed an increase in adduct levels at 6h after mutagen treatment and most showed a significant drop in adduct levels between 6h and 48h (stomach, proximal and distal SI, liver, spleen, blood and lung), one group of tissues displayed O(6)-mdGua levels that did not decrease at 48h (proximal and distal colon, kidney and bladder). Predictably, the colon displayed tumours 26 weeks after treatment. Interestingly, however, the proximal SI also displayed significant tumour formation at that time. Our findings demonstrate (1) a direct association between exposure to O(6)-mdGua and tumours of the distal colon and (2) a dissociation of the relationship between adduct clearance and tumorigenesis in the SI. This diversity of response in the gastrointestinal tract warrants further analysis.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21295156     DOI: 10.1016/j.mrgentox.2010.12.016

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  5 in total

1.  Comparative DNA adduct formation and induction of colonic aberrant crypt foci in mice exposed to 2-amino-9H-pyrido[2,3-b]indole, 2-amino-3,4-dimethylimidazo[4,5-f]quinoline, and azoxymethane.

Authors:  Sangyub Kim; Jingshu Guo; M Gerald O'Sullivan; Daniel D Gallaher; Robert J Turesky
Journal:  Environ Mol Mutagen       Date:  2016-01-06       Impact factor: 3.216

Review 2.  Persistence of DNA adducts, hypermutation and acquisition of cellular resistance to alkylating agents in glioblastoma.

Authors:  R J Head; M F Fay; L Cosgrove; K Y C Fung; D Rundle-Thiele; J H Martin
Journal:  Cancer Biol Ther       Date:  2017-11-20       Impact factor: 4.742

Review 3.  Colorectal carcinogenesis: a cellular response to sustained risk environment.

Authors:  Kim Y C Fung; Cheng Cheng Ooi; Michelle H Zucker; Trevor Lockett; Desmond B Williams; Leah J Cosgrove; David L Topping
Journal:  Int J Mol Sci       Date:  2013-06-27       Impact factor: 5.923

4.  Genomic homeostasis is dysregulated in favour of apoptosis in the colonic epithelium of the azoxymethane treated rat.

Authors:  Caroline A Kerr; Barney M Hines; Janet M Shaw; Robert Dunne; Lauren M Bragg; Julie Clarke; Trevor Lockett; Richard Head
Journal:  BMC Physiol       Date:  2013-01-23

5.  Butyrylated starch affects colorectal cancer markers beneficially and dose-dependently in genotoxin-treated rats.

Authors:  Shusuke Toden; Trevor J Lockett; David L Topping; Benjamin L Scherer; Emma-Jane L Watson; Jessica G Southwood; Julie M Clarke
Journal:  Cancer Biol Ther       Date:  2014       Impact factor: 4.742

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.